Biotech/Pharma Stocks Sector Close- Up- Human Genome Sciences (NASDAQ:HGSI) up over 200%


POINT ROBERTS, Wash., July 20, 2009 www.BiotechIndustryStocks.com, a global investor website for the biotechnology sector within Investorideas.com, presents a biotech stocks sector close- up following sharp gains from Human Genome Sciences (NASDAQ:HGSI).

Biotech Stock News - Human Genome Sciences (NASDAQ:HGSI) and GlaxoSmithKline Announce Positive Phase 3 Study Results for BENLYSTA(TM) in Systemic Lupus Erythematosus

BENLYSTA (Belimumab) Met Its Primary Efficacy Endpoint by Achieving a Statistically Significant Improvement in Patient Response Rate Versus Placebo in BLISS-52; First Drug for Lupus to Reach This Advanced Stage of Clinical Development and Achieve Positive Results, in the Largest Randomized Placebo-Controlled Clinical Trial Ever Completed in SLE Patients

Human Genome Sciences, Inc. (NASDAQ:HGSI) and GlaxoSmithKline PLC (GSK) - July 20, 2009 -today announced that BENLYSTA(TM) (belimumab, formerly LymphoStat-B?) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE). In the placebo-controlled BLISS-52 study, the results showed that BENLYSTA plus standard of care achieved a clinically and statistically significant improvement in patient response rate at Week 52, compared with standard of care alone. Study results also showed that belimumab was generally well tolerated, with adverse event rates comparable between belimumab and placebo treatment groups.
Read full story

Investors can learn how to invest in and trade Biotech/Pharm Stocks with our Biotech Stocks Directory (Includes Stem Cell Stocks), Medical Stocks, Life Sciences and Pharma Stocks at Biotechindustrystocks.com and Investorideas.com

Biotech Stocks Directory Preview:
3SBio Inc. (NasdaqGS:SSRX) 3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China.

Aastrom Biosciences, Inc. (NasdaqCM: ASTM) Aastrom is a leader in the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology involves the use of a patient's own cells to manufacture products to treat a range of chronic diseases and serious injuries. Aastrom's TRC-based products contain increased numbers of stem and early progenitor cells, produced from a small amount of bone marrow collected from the patient. The TRC technology platform has positioned Aastrom to advance multiple products into clinical development. Ongoing development activities are focused on applications of the technology to cardiac and vascular regeneration. The Company currently has a cardiovascular regeneration product in Phase II development for the treatment of dilated cardiomyopathy (DCM) (called the IMPACT-DCM trial) and critical limb ischemia (called the RESTORE-CLI trial).

ABAXIS, Inc. (NasdaqGS: ABAX) Abaxis develops, manufactures and markets portable blood analysis systems for use in any veterinary or human patient-care setting to provide clinicians with rapid blood constituent measurements. The system consists of a compact, 5.1 kilogram (11.2 pounds), portable analyzer and a series of single-use plastic discs, called reagent discs that contain all the chemicals required to perform a panel of up to 13 tests on veterinary patients and 14 tests on human patients. The system can be operated with minimal training and performs multiple routine tests on whole blood, serum or plasma samples. The system provides test results in less than 12 minutes with the precision and accuracy equivalent to a clinical laboratory analyzer.

ABBOTT LABORATORIES (NYSE: ABT) Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

ABIOMED INC (NasdaqGM:ABMD) Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart.

Acadia Pharmaceuticals Inc. (NasdaqGM: ACAD) ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio of its four most advanced product candidates, including pimavanserin in Phase III for Parkinson's disease psychosis, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and ACP-106 in IND-track development. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform.

ACAMBIS PLC ADS (OTCPK:ACAMY) Acambis is a vaccine company developing novel vaccines that address significant unmet medical needs or substantially improve upon current standards of care.

Accentia Biopharmaceuticals, Inc. (OTCPK:ABPIQ) Accentia Biopharmaceuticals, Inc. (Other OTC: ABPI) is committed to building significant value for its stockholders through the commercialization of patent-protected disruptive healthcare technologies designed to be positioned as leading products for the treatment of a broad range of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications.

Acorda Therapeutics, Inc. (NasdaqGM:ACOR) Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Acrongenomics, Inc. (OTCBB: AGNM) Acrongenomics Inc. is a publicly traded company that focuses on investing in and commercializing novel technology platforms concerning the Life Sciences sector. Acrongenomics brings novel and realistic concepts to market by transforming scientific innovations into tangible, consumer-orientated applications. The company has its headquarters in London, England

About Biotechindustrystocks.com:
BiotechIndustryStocks.com is a global meeting place for investors and industry following the biotech sector, within Investorideas.com. Global visitors use the site daily to research the latest biotech stock and industry news, articles, audio, research reports and our stock directories.

Biotech services for investors and publicly traded companies:

Visit the Biotech/Pharma Stock Directory

Biotech public and private companies can submit news releases and press releases : Submit Press Releases

Become a Biotech Showcase company on Investorideas.com and Biotechindustrystocks.com

Submit Your Biotech company profile

About InvestorIdeas.com:
InvestorIdeas.com is a leading global investor and industry research resource portal specialized in sector investing covering over thirty industry sectors and global markets including China, India, the Middle East and Australia.

Investorideas.com Membership – Access full Biotech Stocks Directory, water stocks and more…
With markets and investor sentiment changing daily- it is more important than ever to stay on top of key trends! Gain Exclusive Insight on Leading Sectors, Global Trends, and Insider Trading Ideas, News, Articles and Investor Ideas Members only Restricted Content including the complete renewable energy stocks directory, water stocks, biotech and defense stocks directory, as well as the Insiders Corner by Michael Brush.
Become an InvestorIdeas.com Member

InvestorIdeas.com Disclaimer: www.InvestorIdeas.com/About/Disclaimer.asp
Our sites do not make recommendations, but offer information portals to investors to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. We attempt to research thoroughly, but we offer no guarantees as to the accuracy of any information presented. All information relating to featured companies is sourced from public documents and/ or the company and is not the opinion of our web sites. This site is compensated by featured companies, news submissions and online advertising.

For more information contact:
Dawn Van Zant 800.665.0411 dvanzant@investorideas.com
Or cvanzant@investorideas.com